- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nektar Therapeutics (NKTR)
Nektar Therapeutics stock price live, this page displays NASDAQ NKTR stock exchange data. View the NKTR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nektar Therapeutics real time stock price chart below.
What Is the Nektar Therapeutics Stock Price Today?
The Nektar Therapeutics stock price today is 60.1000.
What Is the Stock Symbol for Nektar Therapeutics?
The stock symbol for Nektar Therapeutics is ""NKTR.""
What Stock Exchange Does Nektar Therapeutics Trade On?
Nektar Therapeutics is listed and trades on the NASDAQ stock exchange.
Is Nektar Therapeutics a Good Stock to Buy?
Determining whether Nektar Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NKTR quote. (ISIN: US6402683063)
What Is the Nektar Therapeutics Stock Price Today?
The Nektar Therapeutics stock price today is 60.1000.
What Is the Stock Symbol for Nektar Therapeutics?
The stock symbol for Nektar Therapeutics is ""NKTR.""
What Stock Exchange Does Nektar Therapeutics Trade On?
Nektar Therapeutics is listed and trades on the NASDAQ stock exchange.
Is Nektar Therapeutics a Good Stock to Buy?
Determining whether Nektar Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NKTR quote. (ISIN: US6402683063)
Fair Value
An estimate of a Nektar's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
59.2349
64.9500
52 wk Range
6.4800
65.7900
NKTR Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
NKTR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Nektar's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
59.234964.9500
52 wk Range
6.480065.7900
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NKTR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Nektar's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
93.8571
Upside
+56.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics Earnings Call Summary for Q2/2025
- Nektar reports Q2 EPS of -$2.78, missing forecasts by 1,290%, while revenue of $11.17M beats expectations by 14.68%
- Stock falls 3.12% post-earnings to $21.75; company maintains $1.08B in cash and investments at quarter-end
- Nektar advances RespEG program, plans Phase III trials in 2026 for atopic dermatitis and alopecia areata
- Company projects $180-$185M cash at 2025-end, ensuring runway into 2027; analysts set price targets of $69-$120
- CEO emphasizes 'first in class novel Treg mechanism'; R&D chief highlights potential in alopecia areata treatment
Last Updated: 08/08/2025, 12:28
Read Full TranscriptCompare NKTR to Peers and Sector
Metrics to compare | NKTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNKTRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.2x | −6.5x | −0.7x | |
PEG Ratio | −0.29 | 0.01 | 0.00 | |
Price/Book | −51.5x | 1.6x | 2.6x | |
Price / LTM Sales | 16.6x | 3.0x | 3.4x | |
Upside (Analyst Target) | 63.0% | 119.7% | 37.6% | |
Fair Value Upside | Unlock | 17.9% | 4.6% | Unlock |
Analyst Ratings
6 Buy
1 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 93.8571
(+56.17% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-2.78 / -0.20
Revenue / Forecast
11.17M / 9.74M
People Also Watch
FAQ
What Stock Exchange Does Nektar Trade On?
Nektar is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Nektar?
The stock symbol for Nektar is "NKTR."
What Is the Nektar Market Cap?
As of today, Nektar market cap is 1.14B.
What Is Nektar's Earnings Per Share (TTM)?
The Nektar EPS (TTM) is -8.72.
From a Technical Analysis Perspective, Is NKTR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Nektar Stock Split?
Nektar has split 2 times.
How Many Employees Does Nektar Have?
Nektar has 61 employees.
What is the current trading status of Nektar (NKTR)?
As of 25 Oct 2025, Nektar (NKTR) is trading at a price of 60.1000, with a previous close of 63.64. The stock has fluctuated within a day range of 59.2349 to 64.9500, while its 52-week range spans from 6.4800 to 65.7900.
What Is Nektar (NKTR) Price Target According to Analysts?
The average 12-month price target for Nektar is USD93.85714, with a high estimate of USD120 and a low estimate of USD30. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +56.17% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.